Market revenue in 2023 | USD 74.2 million |
Market revenue in 2030 | USD 107.5 million |
Growth rate | 5.4% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 60.38% in 2023. Horizon Databook has segmented the Sweden inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
Continuous developments by companies operating in the market are contributing to market growth. For instance, in July 2022, AbbVie announced that the European Commission approved RINVOQ for the treatment of severe to moderate ulcerative colitis. The approval is based on phase III study results, and it is RINVOQ’s fifth therapeutic indication in the European Union.
Furthermore, in November 2021, Galapagos NV announced that the European Commission granted marketing authorization to nilotinib 200 mg tablets for the treatment of moderate to severe ulcerative colitis.
In addition, the growing demand for biosimilars in the country is facilitating its market growth. For instance, in October 2018, Amgen announced that AMGEVITA, a biosimilar approved by European Commission, has been authorized for the management of inflammatory diseases, including psoriatic arthritis and moderate-tosevere Crohn's disease & ulcerative colitis.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into Sweden inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account